KDR and breast cancer: Our results reveal that the GEP100-Arf6-AMAP1-cortactin pathway, activated by growth factor receptor tyrosine kinases, is common in angiogenesis and invasion and metastasis of some breast cancer cells, and hence provides new therapeutic targets for human disorders characterized by hyper-angiogenesis and malignant cancer development.